NCT03713489

Platelet Transfusion in HBV-related acute-on Chronic Liver Failure

Status unknown NA Last updated 22 October 2018

What this trial tests

NA trial testing platelet in Acute-On-Chronic Liver Failure in 20 participants. Status unknown.

Timeline

1 October 2018

Primary endpoint
30 September 2019

30 September 2019

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 October 2018
Primary completion	30 September 2019
Estimated completion	30 September 2019
Sites	1 location across China

Drugs / interventions tested

• platelet

Conditions studied

• Acute-On-Chronic Liver Failure — all drugs for Acute-On-Chronic Liver Failure →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 18 to 60, any sex, with Acute-On-Chronic Liver Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute-on-chronic liver failure (ACLF) is a syndrome that has recently been recognized as encompassing acute deterioration of liver function in patients with pre-existing chronic liver disease. It is associated with multi-organ failure and a high risk of short-term mortality. Thrombocytopenia is common in ACLF. In addition, the function of platelet is also compromised according to our previous data. The aim of this study is to explore whether platelet transfusion could reduce the short-term mortality rate of HBV-related ACLF. This is a single center, open labeled randomized controlled study. There are two arms. Subjects who is assigned to platelet transfusion group will receive both platelet transfusion (9 times/4 weeks, 1 unit each time) and standard medical treatment. While those in standard medical treatment group will receive standard medical treatment only. The major endpoint is 28-day transplant-free mortality rate.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Prophylactic platelet transfusions versus no prophylaxis in hospitalized patients with thrombocytopenia: A systematic review with meta-analysis.
   Anthon CT, Granholm A, Sivapalan P, Zellweger N, et al · · 2022 · cited 12× · PMID 35986657 · DOI 10.1111/trf.17064